1. Valproate augmentation in a subgroup of patients with treatment-resistant unipolar depression
- Author
-
John Tabaka, Gabriella Gobbi, Stefano Comai, Maykel F. Ghabrash, Linda Booij, Marie Saint-Laurent, Ghabrash, Mf, Comai, Stefano, Tabaka, J, Saint Laurent, M, Booij, L, and Gobbi, G.
- Subjects
Adult ,Male ,MADRS ,Canada ,medicine.medical_specialty ,antidepressant activity ,Severity of Illness Index ,Depressive Disorder, Treatment-Resistant ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Severity of illness ,medicine ,CGI ,Humans ,Young adult ,Psychiatry ,Treatment resistant ,Biological Psychiatry ,Depression (differential diagnoses) ,Psychiatric Status Rating Scales ,treatmentresistant depression ,Valproate ,Valproic Acid ,Psychiatric Status Rating Scale ,Middle Aged ,medicine.disease ,Antidepressive Agents ,030227 psychiatry ,Psychiatry and Mental health ,Treatment Outcome ,Psychiatry and Mental Health ,Antidepressive Agent ,Antidepressant ,Female ,lipids (amino acids, peptides, and proteins) ,Animal studies ,Psychology ,Treatment-resistant depression ,030217 neurology & neurosurgery ,Human ,medicine.drug - Abstract
Objectives: About 50% of patients with unipolar depression suffer from treatment-resistant depression (TRD). Animal studies have suggested potential antidepressant properties of valproate (VPA) possibly due to its implication in epigenetic programming. Methods: Fourteen TRD patients (seven males and seven females; age 19-59) received VPA (375-1000 mg/day) in addition to their treatment regimen after previously failing to respond to two or more antidepressant trials and/or different combinations. Clinical response to VPA was investigated prior the treatment (T-0) and after 1 (T-1), 4 (T-4) and 7 (T-7) months of therapy using the Montgomery-Asberg Depression Rating Scale (MADRS) and the Clinical Global Impression (CGI). Results: Compared to T-0, VPA significantly decreased MADRS score at T-1 (P < 0.001), T-4 (P < 0.001) and T-7 (P < 0.001) (partial η2=0.86). Importantly, MADRS score at T-7 (13.6 ± 1.6, mean ± SEM) was closer to the reported value of remission (MADRS
- Published
- 2015
- Full Text
- View/download PDF